About PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic melanocortin receptor agonist developed from the alpha-MSH peptide family. It binds primarily to the MC4 receptor in the central nervous system, where it modulates dopaminergic pathways involved in sexual arousal. Unlike vasodilator-based approaches, PT-141 acts upstream — on the neural pathways that initiate arousal — rather than on peripheral blood flow.

It was originally developed as an intranasal product but reformulated for subcutaneous injection after blood-pressure variability concerns. The injectable form (marketed as Vyleesi in the US for hypoactive sexual desire disorder in pre-menopausal women) is the pharmacologically approved form. Research-grade vials are studied for both male and female sexual function applications.

Dosing observed in research literature

Application	Dose	Frequency	Notes
Standard research dose	1.75 mg	As-needed, 45 min before activity	Approved clinical dose for HSDD
Lower-range research	1.0 mg	As-needed	Reduces nausea incidence vs full dose
Higher-range research	2.0–3.0 mg	As-needed	Increased side-effect risk; not standard

PT-141 is typically dosed on-demand rather than on a daily schedule. Maximum recommended frequency in research is one dose per 24 hours and no more than eight doses per month. Effects typically begin within 30–60 minutes and last 6–10 hours.

Typical reconstitution protocols

PT-141 ships as a 10 mg lyophilised vial. Reconstitution recommendations:

Vial size	Recommended BAC water	Concentration	1.75 mg draw	1.0 mg draw
10 mg	1 mL	10 mg / mL	17 units (U-100)	10 units
10 mg	2 mL	5 mg / mL	35 units	20 units
10 mg	2.5 mL	4 mg / mL	~44 units	25 units

The 2 mL reconstitution lands a 1.75 mg draw at a clean 35 units on a U-100 syringe — easy to measure, easy to repeat. Lower BAC volumes concentrate the solution but make small-error tolerance worse.

Half-life and frequency

Plasma half-life of subcutaneous PT-141 is approximately 1.9–2.7 hours. The pharmacodynamic effect outlasts plasma concentration — measurable behavioural effects persist for 6–10 hours after dosing. Because dosing is on-demand rather than cumulative, frequency is set by user need rather than receptor saturation, with the 24-hour and 8-dose-per-month limits applied as safety windows.

Storage and shelf life

Lyophilised: store at 2–8°C refrigerated. Reconstituted with bacteriostatic water: stable for up to 28 days refrigerated. Don’t freeze a reconstituted vial. Some research protocols favour using PT-141 within 14 days of reconstitution to ensure full potency given its on-demand use pattern.

Frequently asked questions

How long before activity should PT-141 be dosed?

Standard research protocols recommend administration approximately 45 minutes before anticipated activity. Onset typically begins within 30 minutes and peaks around 60–90 minutes after dosing.

What are the common side effects?

Most-reported in clinical trials: nausea (40% at full dose, 13% at low dose), flushing, headache. Transient blood pressure increase (~6 mmHg systolic on average) is documented; research protocols typically exclude subjects with uncontrolled hypertension. Nausea is dose-dependent and reduces sharply at 1.0–1.5 mg.

Is PT-141 still available as an intranasal product?

The intranasal formulation was discontinued during development due to blood-pressure variability — the subcutaneous route gives more predictable absorption. Some research-grade suppliers still sell intranasal PT-141, but the subcutaneous form is the standard for protocol work.

What’s the difference between PT-141 and Melanotan II?

Both are melanocortin receptor agonists, but PT-141 binds primarily MC4 (CNS, behavioural effects) while Melanotan II binds MC1 + MC3 + MC4 (broad activity including tanning effects). PT-141 doesn’t produce skin pigmentation; MT2 does. They have related chemistry but different research uses.

Can PT-141 be used daily?

Not in standard research protocols. The clinical protocol limits dosing to no more than once per 24 hours and no more than 8 doses per month. Daily continuous use has not been studied for safety and may accelerate receptor desensitisation.

What injection site is used for PT-141 research?

Subcutaneous abdominal injection is the standard. Thigh is the documented alternative. Because dosing is on-demand rather than chronic, site rotation is less critical than for daily-dosed peptides.

Related compounds

PT-141 sits in the specialty research category. Adjacent: Melanotan II (related melanocortin family, broader receptor binding), Oxytocin (related neuropeptide research, different mechanism). For full category overview, see Specialty Research Compounds.